Omesec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omesec

Quick Facts: Omesec Identity

Property Description
Active ingredient Omeprazole (INN)
Form Delayed-release capsule or tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General use Reduction of gastric acid hyperacidity
Origin Synthetic Benzimidazole derivative

Omesec: Identity, Composition, and Pharmacological Class

Omesec is a medicinal product containing the active component Omeprazole, which is categorized as a Proton Pump Inhibitor (PPI). Omeprazole is a synthetic compound known chemically as a Benzimidazole derivative, functioning as an antiulcer agent. Omeprazole is classified as a member of the proton pump inhibitor class. This mechanism confirms that the medication acts by specifically blocking the cellular machinery responsible for acid production. The clinical efficacy of Omeprazole is supported by pharmacological studies and is globally recognized as a standard for acid control.

What is the General Purpose of Omesec?

The fundamental purpose of Omesec is to provide sustained gastric acid secretion inhibition, effectively reducing the total volume of acid produced in the stomach. By regulating the amount of acid within the gastric lumen, the medicine serves the general therapeutic goal of managing acid-related disorders that arise from gastric hyperacidity. This action alleviates the irritation and supports the healing process for the stomach and esophagus lining.

Omesec is manufactured for oral administration and is typically presented as a specialized delayed-release capsule or tablet formulation. This design is critical because Omeprazole is highly vulnerable to degradation by stomach acid. The delayed-release mechanism ensures the active ingredient bypasses the stomach acid, allowing it to be properly absorbed in the small intestine to reach the parietal cells where the acid pumps are located.

Regulatory References

  1. MedlinePlus - Omeprazole
  2. Proton Pump Inhibitor (PPI)
  3. acid-related disorders

What side effects are possible with Omesec?

Possible Side Effects and Safety Information

The safety profile for Omeprazole (Omesec) is formally documented in regulatory sources based on frequency classifications and affected System-Organ Classes (SOCs). The most common adverse reactions are related to the Gastrointestinal and Nervous systems, including headache, abdominal pain, constipation, diarrhea, flatulence, and nausea.

Officially Documented Safety Considerations

Category Description from Regulatory Labeling
Uncommon Effects Include reactions such as insomnia, dizziness, somnolence (drowsiness), rash, and pruritus (itching).
Serious Adverse Reactions Officially documented rare events include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as anaphylactic reactions and severe hepatic failure.
Time-Related Patterns Specific risks are associated with prolonged use (typically one year or longer), including the development of Hypomagnesemia (low magnesium levels) and an increased risk of bone fracture.
Population Notes The increased risk of bone fracture is specifically noted for long-term therapy in older adults. Safety monitoring may be warranted for individuals with severe hepatic impairment.
High-Level Constraints The labeling notes formal restrictions, such as contraindication for use with Nelfinavir, and cautions regarding high-level safety consequences with co-administration of Clopidogrel or Methotrexate.

This organized framework allows regulatory authorities to provide a standardized, medically grounded description of the known risks associated with the medicine, without interpretation or advisory content.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory reports for Omeprazole (Omesec) overdosage, including cases involving doses up to 900 mg (up to 45 times the recommended daily dose), indicate that documented clinical manifestations are generally transient and non-serious. Symptoms officially reported include neurological effects such as confusion and drowsiness, gastrointestinal signs like nausea and dry mouth, and other manifestations such as blurred vision, flushing, headache, and tachycardia (rapid heart rate).

In the event of suspected overdosage, it is officially mandated to seek immediate medical attention or contact a poison control helpline. Treatment for Omeprazole overdosage is entirely symptomatic and supportive, as official labeling confirms that no specific antidote is known. Furthermore, regulatory information notes that Omeprazole is extensively protein bound and is therefore not readily dialyzable, limiting certain procedural interventions.

Urgent contact with emergency services (e.g., 911) is strictly required if the individual exhibits critical, potentially life-threatening symptoms. These specific emergency triggers, as described in government documentation, include loss of consciousness (collapse), the presence of a seizure, or severe difficulty breathing. The official overdose section does not specify distinct management considerations for particular populations (e.g., pediatric or elderly patients).

Therapeutic Uses of Omesec

What Omesec Treats: Main Uses and Benefits

Omesec is commonly used for managing symptoms across a variety of acid-related disease management therapeutic domains, providing supportive relief for conditions associated with acute or disruptive episodes. This medication is applied in conditions where symptoms may intensify temporarily, and is considered relevant for easing related symptoms.

Omesec is relevant for conditions presenting with acute or recurrent manifestations, including Gastroesophageal Reflux Disease (GERD), peptic ulcers (both gastric and duodenal), and erosive esophagitis. It is also used for managing severe symptomatic distress in rare situations like Zollinger-Ellison Syndrome and is part of the combination therapy for H. pylori infection.

The application is relevant when supportive symptom management is appropriate, as it helps address symptom clusters that may become intense or disruptive. The assistance is helpful during phases of increased distress.

“Omesec provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

It is further applied in specialized scenarios, offering symptomatic assistance for high-risk individuals, such as critically ill patients requiring stress ulcer prophylaxis, and managing severe reflux symptoms in specific pediatric patient groups over one month of age.

Quick Fact: Relief for Acid-Related Symptoms
Symptom Domains Heartburn, acid regurgitation, epigastric burning, ulcer-related pain.
Use Context Situations requiring short-term relief, contexts involving recurrent or episodic manifestations, and supportive combination therapy.
Core Benefit Supports patients during difficult episodes by easing distress. May assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Omesec?

The population eligibility for Omeprazole (Omesec) is defined strictly by regulatory labeling, outlining specific groups for whom use is permitted, restricted, or contraindicated. This information is based on official government documentation from agencies such as the FDA and EMA.


Absolute Contraindications

Use of Omesec is formally contraindicated in patients with a known hypersensitivity to the active substance, omeprazole, or to any substituted benzimidazoles. It is also prohibited for patients concurrently receiving the antiretroviral medication nelfinavir.


Age-Related Eligibility

The medicine is generally allowed for adults and pediatric patients 1 year of age and older. Use is formally approved for the treatment of certain acid-related disorders in pediatric patients as young as 1 month of age. However, safety and effectiveness have not been established in infants under 1 month of age.


Population Restrictions

Population Group Regulatory Status
Hepatic Impairment Use requires consideration of a dose reduction due to altered metabolism.
Renal Impairment Dose adjustment is not needed based on kidney function.
Hereditary Disorders Not recommended for patients with specific hereditary conditions, such as Lapp lactase deficiency, due to excipients in certain formulations.

Pregnancy and Lactation

Omeprazole is excreted into human milk. The official label advises that a decision must be made whether to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Omeprazole, the active component in Omesec, has officially documented interaction patterns categorized by two primary mechanisms: metabolic pathway modulation and gastric acidity dependency.

Pharmacokinetic and Pharmacodynamic Interactions

Omeprazole is a known inhibitor of the CYP2C19 enzyme. This pharmacokinetic effect can reduce the clearance and increase the systemic exposure of other medicines metabolized by this enzyme, including Cilostazol, Diazepam, and the anticoagulants like Warfarin. Conversely, co-administration with enzyme inducers such as Rifampin or the herbal product St. John’s Wort is documented to reduce Omeprazole’s plasma concentrations.

The pharmacodynamic effect of acid suppression alters the absorption of other substances that require an acidic gastric environment. This results in reduced plasma levels for certain medicines, including the antifungals Ketoconazole and Itraconazole, and the HIV antivirals Atazanavir and Nelfinavir.

Official Restrictions and Constraints

Restriction Type Specific Substance or Context
Formal Contraindication Co-administration with Rilpivirine is contraindicated due to the risk of reduced antiviral plasma concentrations.
Timing Requirement Discontinuation of treatment is required for at least 14 days before measuring plasma Chromogranin A (CgA) levels, as Omeprazole interferes with this diagnostic test.

Individuals identified as CYP2C19 poor metabolizers exhibit higher systemic exposure to Omeprazole, which may impact the clinical relevance of other CYP2C19-mediated interactions.

Mechanism of Action

Omeprazole works by targeting the enzyme system responsible for creating stomach acid. Its mechanism involves two core domains that result in a significant and sustained alteration of gastric pH.

Irreversible Blockade of the Proton Pump

The drug acts as an acid-activated prodrug that travels to the stomach's parietal cells, where it is converted into its active form by the acidic environment. It then forms a permanent, covalent bond with the H^+/ K^+- ATPase enzyme (the Proton Pump), which is the final step in hydrochloric acid ( HCl) secretion. This action results in final common pathway inhibition, which modulates acid extrusion regardless of upstream cellular stimuli (food, gastrin, or histamine).


⏱ Sustained Control Through Cellular Renewal

Because the drug's inhibition is irreversible—the pump is permanently disabled—the return of acid secretion is solely dependent on the parietal cell’s ability to synthesize and insert new H^+/ K^+- ATPase molecules into its membrane. This biological process of protein renewal dictates the duration of the drug’s physiological action, resulting in a sustained reduction in intragastric acidity that persists beyond the drug's plasma half-life.

Dosage and Administration Information

How to Use Omesec

Omesec (Omeprazole) is primarily administered via the oral route using delayed-release capsules, delayed-release tablets, or an oral suspension. An intravenous (IV) infusion is available for situations where oral use is not feasible. The specific usage parameters focus on dosing, frequency, and administration conditions.


Standard Usage Patterns

Usage Instruction General Parameters
Route & Form Oral (capsule, tablet) or IV infusion. Oral forms must be swallowed whole and not chewed or crushed, as the protective coating is essential for delivery.
Timing & Frequency Dosing is typically once daily, administered before a meal (usually in the morning). Twice daily dosing is specified for certain combination therapies, such as the H. pylori eradication regimen.
Standard Dosing Standard adult doses range from 10 mg to 40 mg once daily for most conditions. For Pathological Hypersecretory Conditions (like Zollinger-Ellison Syndrome), initial doses are higher (60 mg) and may be adjusted upwards, with daily totals over 80 mg requiring administration in divided doses.
Duration Patterns Use is short-term (e.g., 4 to 8 weeks) for acute conditions, or long-term for maintenance and certain complex disorders.

Population and Procedural Rules

Certain instructions apply to specific groups: patients with hepatic impairment may require a lower daily dose (e.g., maximum 20 mg) due to altered clearance. Pediatric dosing (for children over one year) is weight-based. If a dose is missed, the procedure involves taking it only if the next scheduled dose is more than 12 hours away; otherwise, the missed dose should be skipped, maintaining the regular schedule. These procedural requirements ensure the medicine is used according to its specifications.

Recent Clinical Evidence

Research evidence / Overview of studies for Omesec

The research evidence for Omesec (Omeprazole) is drawn from formal clinical evaluations, including numerous randomized controlled trials (RCTs), systematic reviews, and meta-analyses. These studies are conducted under specific conditions and monitored for outcomes related to physical discomfort and functional imbalance.


Research Evidence for GERD and Symptomatic Reflux

Research has explored the use of Omesec in conditions such as Gastroesophageal Reflux Disease (GERD) and erosive esophagitis. Studies were primarily conducted as short-term RCTs to observe the measurement of tissue damage and the evolution of symptoms over defined time intervals, usually between four and eight weeks. Studies monitored outcomes related to physical discomfort, such as the measurement of changes in heartburn and acid regurgitation, and utilized endoscopic confirmation to measure mucosal lesion closure in the esophagus. Long-term outcomes regarding the sustained absence of symptoms beyond one year are not fully established in large-scale randomized trials.


Research Evidence for Ulcer Healing and Prevention

Omesec was evaluated in studies focusing on acute lesion closure and subsequent prevention of recurrence for both gastric and duodenal peptic ulcers. The research utilized short-term RCTs to assess acute closure, and longer-term observational studies to explore patterns related to ulcer recurrence. Research examined outcomes such as the confirmation of ulcer closure via follow-up endoscopy and the recorded rate at which new ulcers formed during extended maintenance periods. Comparative evidence regarding long-term recurrence rates is an area where research is ongoing.


Research Evidence for H. pylori Eradication Therapy

Omesec was studied for its use as a component within multi-drug combination regimens aimed at eradicating the Helicobacter pylori organism. This research primarily involved short-term (7- to 14-day) RCTs designed to assess the microbiological outcome. Studies monitored the eradication rate of the bacteria, which was typically confirmed four to eight weeks after the completion of the regimen. Research describes that the findings indicate an association between adherence to the full regimen and the measured eradication rate.


Evidence in Specific Patient Groups and Research Gaps

Omesec was evaluated in research involving specific populations, including pediatric patients over one month of age with severe GERD, and studies have explored the patterns observed in older adults. The body of research has certain limitations; follow-up durations were limited in many initial RCTs, and data for certain groups, such as those with complex underlying health conditions, remain insufficient. The extended application for many conditions remains an area where research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Omesec (FAQ)

Q: Can Omesec be taken long-term?

Official product information notes that use is specified for short-term treatment or long-term maintenance depending on the condition. However, regulatory documents state that use for one year or longer has been associated with documented risks. These risks include the potential for developing hypomagnesemia (low magnesium levels) and an increased risk of bone fracture.

Q: Does Omesec affect other vitamins or supplements I might take?

Studies and official information indicate that long-term use may interfere with the gastrointestinal absorption of vitamin B12. The body relies on stomach acid to properly absorb this vitamin, and Omesec reduces acid production. For this reason, official sources note that B12 levels may warrant monitoring during extended therapy.

Q: Why are there different strengths of Omesec available?

Different strengths of the medicine are available to address the wide range of approved medical conditions. Standard doses for most conditions are lower, but certain severe or rare conditions, such as Pathological Hypersecretory Conditions, require higher daily doses. These higher doses are sometimes taken in divided amounts to manage symptoms.

Q: What is the longest period Omesec has been studied for continuous use?

Official research has examined the effects of continuous use on the cells of the stomach lining. Studies have noted that the incidence of ECL cell hyperplasia (an increase in certain cells) rises with time. However, regulatory documents note that these studies were not long enough to fully rule out the potential for long-term, rare safety concerns.

Q: What should I do if I am already taking Omesec and my doctor prescribes another medicine?

Omeprazole has documented interaction patterns that can change how other medicines work in the body, either through the drug's effect on metabolism or by reducing stomach acid. Official interaction guidance highlights the importance of informing a healthcare provider about all concurrent medicines being taken, including over-the-counter products and supplements.

Q: How quickly does Omesec start to help with symptoms?

According to the official product information for the over-the-counter formulation, the medicine is not intended for immediate relief. Symptom relief may begin within the first 24 hours for some people, but it is typically expected to take one to four days to achieve its full effect.

Q: Can Omesec cause a metallic taste in the mouth?

Official safety reports list taste perversion or taste disturbances as potential effects, which may affect up to 15% of people. These effects alter how things taste or may leave an unpleasant taste sensation, such as a metallic taste, in the mouth.

Q: Is it possible for Omesec to stop working after a while?

Prolonged use of the medication may be associated with rebound acid hypersecretion if treatment is stopped suddenly. This is a temporary increase in acid production that may cause a return or worsening of symptoms, which could be perceived as the drug having stopped working.

Q: Does Omesec have any warnings related to heart health?

Regulatory labeling emphasizes that certain severe symptoms, such as chest pain or shoulder pain accompanied by shortness of breath, sweating, or dizziness when experiencing heartburn, require immediate medical evaluation. This guidance is included to help distinguish between heartburn and symptoms of more serious, non-acid-related heart conditions.

Q: Is Omesec available over-the-counter in some places?

The active ingredient in Omesec is available in some regions in both prescription and lower-strength over-the-counter (OTC) formulations. The OTC strength is specifically approved for adults for the treatment of frequent heartburn, which occurs two or more days per week.

Q: What if I experience unusual tiredness while on Omesec?

Official safety reports list somnolence (drowsiness) as an uncommon effect. Post-marketing and common reports have also included the general feelings of fatigue and asthenia (physical weakness or lack of energy).

Q: Are there common signs that Omesec is not suitable for me?

Official regulatory documents describe serious adverse reactions, including signs of hypersensitivity such as hives, swelling of the face, or difficulty breathing. These symptoms are listed as reactions requiring immediate medical evaluation, as they may indicate the medicine is not suitable for the individual.

Q: Is there a generic version of Omesec?

Yes, the active component of Omesec, called Omeprazole, is widely available in many regions globally as a generic medication that contains the same active ingredient.

Q: Are there any regulatory warnings about taking Omesec with alcohol?

Formal interaction checks in regulatory-backed databases generally indicate that there is no formal drug-drug interaction reported between omeprazole and alcohol.

Q: If I stop taking Omesec, will my symptoms immediately return?

Regulatory guidance on discontinuation notes that stopping prolonged treatment may lead to a phenomenon called rebound acid hypersecretion. This temporary increase in acid production can cause a recurrence or worsening of symptoms like heartburn compared to pre-treatment levels.

Q: Are allergic reactions to Omesec common?

According to official safety documentation, serious allergic reactions, including anaphylactic shock, are listed as rare adverse events. A rare incidence is typically defined as occurring in 0.01% to 0.1% of patients.

Q: What information exists about Omesec and stomach infections?

Regulatory-backed information indicates that studies suggest PPI use may be associated with an increased risk of Clostridioides difficile-associated diarrhea (CDAD). This type of severe diarrhea is especially noted in studies involving hospitalized patients.

Q: Do any official documents describe Omesec as having a potential for dependency?

Official discussions about rebound acid hypersecretion note that the resulting return or worsening of symptoms upon stopping the medicine can make it difficult for people to discontinue use. This difficulty in stopping the drug is the factor that may lead to people becoming reliant on it.

Q: Is Omesec a medicine that must be gradually stopped?

Regulatory guidance suggests that a gradually reducing the dose or step-down approach may be considered for patients discontinuing prolonged PPI therapy. This method is intended to help minimize the potential for developing the rebound acid symptoms mentioned in official sources.

Q: Are there any known interactions between Omesec and caffeine?

While a formal drug-drug interaction between Omesec and caffeine is not typically listed, some regulatory-backed guidance indicates that the medicine is often taken about one hour prior to consuming coffee or other highly acidic beverages. This helps ensure the drug can begin to act before consuming substances that promote acid production.

Q: What does official guidance say about using Omesec for occasional heartburn?

The official guidance for the over-the-counter formulation states that it is specifically approved for treating frequent heartburn (occurring two or more days per week). It is not intended for use in immediate relief situations or for the treatment of only occasional heartburn.

Q: Is Omesec associated with any breathing problems?

Official reports on the safety profile list effects on the respiratory system, including common reports of cough and upper respiratory infection. More serious, but rare, respiratory events such as bronchospasm (narrowing of airways) are also listed in regulatory safety documentation.

Q: Are there different names or brands for the same drug as Omesec?

Yes, the active component of Omesec is Omeprazole, and it is sold in regions around the world under numerous other brand names. These include brands such as Prilosec and Losec.

How should Omesec be stored and disposed of?

Storage and Disposal of Omesec (Omeprazole)

Omesec delayed-release capsules must be stored according to specific regulatory requirements to maintain product stability and safety.

Official Storage Conditions

Requirement Description (From Regulatory Labeling)
Temperature Store at Controlled Room Temperature, 20 mathrmC to 25 mathrmC (68 mathrmF to 77 mathrmF).
Protection Must be protected from moisture and high heat.
Container Keep in the original container and ensure it is tightly closed.
Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Omesec must be disposed of safely. The product should not be flushed down a toilet or poured down a sink. The preferred method is disposal through an official medicine take-back program or authorized collector.

If disposal in household trash is necessary, the medication must be mixed with an unappealing substance, such as dirt or used coffee grounds, and then placed in a sealed bag or container before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omesec found in:

A-Z Index: